The soluble guanylyl cyclase activator BAY 60-2770 ameliorates detrusor dysfunction in obese mice Gilberto de Nucci 1,2* , Luiz Osorio Leiria 1 , Fábio Henrique da Silva 1 , Eduardo C Alexandre 1 , Marina Calixto 1 , Fabíola Zakia Mónica 1 
, Edson Antunes 1
From 6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications Erfurt, Germany. 28-30 June 2013
Background
The obesity-associated insulin resistance has been shown to play an important role in the pathophysiology of overactive bladder in mice [1, 2] . Therefore, we evaluated the beneficial effects of long-term administration of the sGC activator BAY 60-2270 in bladders from lean and obese mice.
Methods
Mice were fed for 12 weeks with either a standard chow diet (carbohydrate: 70%; protein: 20%; fat: 10%) or a high fat diet that induces obesity (carbohydrate: 29%; protein: 16%; fat: 55%). Lean and obese mice were orally treated with BAY 60-2770 (1 mg/kg/day, given as daily gavage from the 10 th to the 12 th week) or its vehicle (Transcutol ® : Cremophor ® :water, 1:2:7, v/v/v). Concentration-response curves to full agonist carbachol (CCh, 0.001-100 µM) were obtained. The values of potency (pEC 50 ) and maximal responses (E max ) were calculated. The cGMP levels and Western blotting for α 1 and β 1 -subunit of sGC in the bladder tissues were also determined.
Results
Contractile response to the muscarinic agonist carbachol was greater (p<0.05, n=5) in bladder from the obese in comparison with lean group. Long-term treatment with BAY 60-2770 normalized the enhanced contractile responses of the obese group, driving it to control levels (p<0.05; figure 1 ). The cGMP levels in the bladder tissues from obese group were significantly lower in comparison with lean mice (0.27 ± 0.04 and 0.95 ± 0.14 pmol/mg tissue, respectively, p<0.05, n=5). Treatment with BAY 60-2770 generated a 10-fold increase (p<0.01) in the bladder cGMP levels of obese mice, without affecting the levels in the lean group (Figure 2A ). Protein expression of α 1 and β 1 subunits of sGC was decreased by 41% and 43% (p<0.05) in bladder tissues of obese animals, respectively. However, oral treatment with BAY 60-2770 restored the protein levels of α 1 and β 1 subunits to that of lean group (Figure 2B and 2C) .
Conclusion
Chronic treatment with BAY 60-2770 results in amelioration of bladder dysfunction in high-fat obese mice. 
